We are live on ! Find out more
RP

Rowlandmiller & Partners Portfolio holdings

AUM $549M
1-Year Est. Return 36.2%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+36.2%
3 Year Est. Return
+84%
5 Year Est. Return
+107.35%
10 Year Est. Return
+338.51%
AUM
$236M
AUM Growth
+$9.34M
Cap. Flow
+$4.9M
Cap. Flow %
2.07%
Top 10 Hldgs %
33.69%
Holding
131
New
3
Increased
44
Reduced
53
Closed
7

Top Buys

Rank Stock Value
1
MDXG icon
MiMedx Group
MDXG
+$2.74M
2
CMP icon
Compass Minerals
CMP
+$1.1M
3
ACH
Accendra Health
ACH
+$755K
4
QCOM icon
Qualcomm
QCOM
+$658K
5
CVX icon
Chevron
CVX
+$627K

Top Sells

Rank Stock Value
1
VAL
Valspar
VAL
+$1.11M
2
GE icon
GE Aerospace
GE
+$537K
3
COP icon
ConocoPhillips
COP
+$377K
4
NUE icon
Nucor
NUE
+$336K
5
CTAS icon
Cintas
CTAS
+$320K

Sector Composition

Rank Sector Weight
1 Technology 16.24%
2 Healthcare 15.42%
3 Financials 14.56%
4 Consumer Staples 14.32%
5 Consumer Discretionary 12.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WFM
26
DELISTED
Whole Foods Market Inc
WFM
$3.34M 1.42%
79,325
-669
-0.8% -$24.4K
XRAY icon
27
Dentsply Sirona
XRAY
$2.68B
$3.31M 1.4%
51,128
+902
+2% +$57K
UPS icon
28
United Parcel Service
UPS
$88.6B
$3.19M 1.35%
28,796
+590
+2% +$63.1K
MRK icon
29
Merck
MRK
$322B
$3.18M 1.35%
51,910
-3,930
-7% -$239K
KMB icon
30
Kimberly-Clark
KMB
$36.3B
$3.16M 1.34%
24,428
-10
-0% -$1.3K
COP icon
31
ConocoPhillips
COP
$147B
$3.11M 1.32%
70,228
-8,090
-10% -$377K
MDXG icon
32
MiMedx Group
MDXG
$602M
$3.04M 1.29%
+205,000
New +$2.74M
CSX icon
33
CSX Corp
CSX
$93.4B
$2.89M 1.22%
158,697
-1,569
-1% -$26.9K
TECH icon
34
Bio-Techne
TECH
$11.2B
$2.58M 1.09%
87,600
-2,000
-2% -$54.7K
BMS
35
DELISTED
Bemis
BMS
$2.54M 1.08%
54,821
-1,158
-2% -$53.3K
TFX icon
36
Teleflex
TFX
$6.05B
$2.44M 1.03%
11,704
-743
-6% -$149K
CMI icon
37
Cummins
CMI
$87.5B
$2.28M 0.97%
14,035
+2,680
+24% +$416K
ZBRA icon
38
Zebra Technologies
ZBRA
$14B
$2.21M 0.94%
21,958
+790
+4% +$78.2K
SON icon
39
Sonoco
SON
$5.57B
$2.16M 0.92%
42,023
-493
-1% -$25.4K
PFE icon
40
Pfizer
PFE
$143B
$2.1M 0.89%
65,948
-436
-0.7% -$13.8K
DUK icon
41
Duke Energy
DUK
$97.8B
$2.03M 0.86%
24,286
-232
-0.9% -$19.5K
CPRT icon
42
Copart
CPRT
$27B
$1.93M 0.82%
242,596
-1,908
-0.8% -$14.6K
AFL icon
43
Aflac
AFL
$64.9B
$1.89M 0.8%
48,622
+2,250
+5% +$84.5K
DVN icon
44
Devon Energy
DVN
$52.1B
$1.81M 0.77%
56,222
-780
-1% -$28.5K
CMP icon
45
Compass Minerals
CMP
$1.23B
$1.81M 0.77%
27,695
+16,510
+148% +$1.1M
PAYX icon
46
Paychex
PAYX
$41.6B
$1.75M 0.74%
30,715
-559
-2% -$32.8K
MDP
47
DELISTED
Meredith Corporation
MDP
$1.53M 0.65%
25,700
+10,370
+68% +$606K
BBBY
48
DELISTED
Bed Bath & Beyond Inc
BBBY
$1.51M 0.64%
49,448
+8,440
+21% +$305K
GL icon
49
Globe Life
GL
$14.2B
$1.46M 0.62%
19,075
-62
-0.3% -$4.71K
JWN
50
DELISTED
Nordstrom
JWN
$1.41M 0.6%
29,268
+658
+2% +$29.9K

Similar funds

Rowlandmiller & Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Rowlandmiller & Partners held 131 positions worth $236M, up 4.1% from $227M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rowlandmiller & Partners's Q2 2017 filing shows 3 new, 44 increased, 53 reduced and 7 closed positions. Its largest new stake was MiMedx Group: 205,000 shares worth $3.04M. The largest sale was Valspar, an estimated $1.11M.

By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 17% a quarter earlier, followed by Healthcare and Financials.

  • Rowlandmiller & Partners's largest Q2 2017 buy was MiMedx Group: 205,000 shares worth $3.04M.
  • Rowlandmiller & Partners added most to Compass Minerals in Q2 2017, an estimated $1.1M increase.
  • Rowlandmiller & Partners's biggest Q2 2017 reduction was GE Aerospace, cutting an estimated $537K.
  • Rowlandmiller & Partners fully exited Valspar in Q2 2017, selling an estimated $1.11M.
  • Rowlandmiller & Partners's ten largest holdings make up 34% of its $236M portfolio in Q2 2017.
  • Rowlandmiller & Partners opened 3 new positions and closed 7 in Q2 2017.
  • Rowlandmiller & Partners's portfolio value rose 4.1% quarter-over-quarter to $236M.

Based on Rowlandmiller & Partners's 13F filing for Q2 2017, filed 15 Aug 2017.